What’s New
- FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
- Circulating Tumor Cells May Predict Prostate Cancer Survival
- Exercise Benefits In Prostate Cancer Active Surveillance
- PARP Inhibitors in Metastatic Prostate Cancer
- Older Men Increasingly Overtreated for Prostate Cancer